布瑞那韋
化合物
布瑞那韋(INN:Brecanavir;開發代號:GW640385),或譯作貝卡那韋、瑞卡那韋,是一種蛋白酶抑制劑,已被研究用於治療艾滋病毒。[1]
臨床資料 | |
---|---|
ATC碼 |
|
識別資訊 | |
| |
CAS號 | 313682-08-5 |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C33H41N3O10S2 |
摩爾質量 | 703.82 g·mol−1 |
3D模型(JSmol) | |
| |
|
參見
參考資料
- ^ Hazen R, Harvey R, Ferris R, et al. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob. Agents Chemother. September 2007, 51 (9): 3147–54. PMC 2043237 . PMID 17620375. doi:10.1128/AAC.00401-07.
- ^ GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385) (新聞稿). GlaxoSmithKline. 2006-12-18 [2008-06-11]. (原始內容存檔於2008-12-03).